Scholar Rock Holding (SRRK) Non-Current Assets (2017 - 2026)
Scholar Rock Holding's (SRRK) quarterly Non-Current Assets came in at $20.0 million in Q1 2026, down 10.47% year-on-year from $22.3 million in Q1 2025, and up 4.42% quarter-over-quarter from $19.1 million in Q4 2025.
Scholar Rock Holding (SRRK) Non-Current Assets (2017 - 2026) Analysis & Trends
Scholar Rock Holding's Non-Current Assets history runs 10 years deep, the most recent figure standing at $20.0 million for Q1 2026.
- On a quarterly basis, Non-Current Assets fell 10.47% year-over-year to $20.0 million in Q1 2026; TTM through Mar 2026 was $81.0 million, a 18.98% decrease from a year earlier, with the FY2025 full-year figure at $19.1 million, down 19.5% from the prior year.
- Non-Current Assets climbed to $20.0 million in Q1 2026 per SRRK's latest filing, from $19.1 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $37.4 million in Q1 2022 and bottomed at $19.1 million in Q4 2025.
- The 5-year median for Non-Current Assets is $23.8 million (2024), against an average of $25.5 million.
- Across the five-year window, Non-Current Assets slumped 32.02% in 2023 and increased 17.92% in 2024, its largest moves.
- Year by year, Non-Current Assets stood at $30.1 million in 2022, then declined by 24.23% to $22.8 million in 2023, then rose by 4.01% to $23.8 million in 2024, then slipped by 19.5% to $19.1 million in 2025, then gained by 4.42% to $20.0 million in 2026.
- Per Business Quant, the three latest SRRK Non-Current Assets figures stand at $20.0 million (Q1 2026), $19.1 million (Q4 2025), and $21.0 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 21.65 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 5.83 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.95 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 3.95 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.75 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 22.66 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.96 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 285.82 Mn |
| 10 | Scholar Rock Holding | 6.30 Bn | 6.30 Bn | - | 19.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 19.97 Mn |
| Dec 31, 2025 | 19.13 Mn |
| Sep 30, 2025 | 21.01 Mn |
| Jun 30, 2025 | 20.92 Mn |
| Mar 31, 2025 | 22.31 Mn |
| Dec 31, 2024 | 23.76 Mn |
| Sep 30, 2024 | 26.21 Mn |
| Jun 30, 2024 | 27.73 Mn |
| Mar 31, 2024 | 20.35 Mn |
| Dec 31, 2023 | 22.84 Mn |
| Sep 30, 2023 | 22.22 Mn |
| Jun 30, 2023 | 25.09 Mn |
| Mar 31, 2023 | 27.56 Mn |
| Dec 31, 2022 | 30.14 Mn |
| Sep 30, 2022 | 32.69 Mn |
| Jun 30, 2022 | 34.99 Mn |
| Mar 31, 2022 | 37.39 Mn |
| Dec 31, 2021 | 39.13 Mn |
| Sep 30, 2021 | 40.23 Mn |
| Jun 30, 2021 | 41.69 Mn |